한국형 우울장애 약물치료 알고리듬 2017(IV) : 임상 아형

Abstract

Objectives : Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) was produced based on revision of the third version, Korean Medication Algorithm Project for Depressive Disorder 2012 (KMAPDD 2012). KMAP-DD 2017 reflects the latest trends and new research in the treatment of depression. Methods : A total of 144 psychiatrists with excellent clinical experience and academic achievements in treating depression were selected. The survey of KMAP-DD 2017 was sent to them through e-mail. Of these, 79 psychiatrists answered the survey. The survey consisted of 44 questionnaires including seven parts. Each treatment strategy was categorized into three classifications of recommendation as first-line, second-line, and third-line, based on the 95% confidence interval. Results : The results of KMAP-DD 2017 were almost similar to those of KMAP-DD 2012. However, the preference for serotonin-norepinephrine reuptake inhibitor such as venlafaxine was increased, as compared with KMAP-DD 2012. In case of anxious distress and mixed features, the preference for atypical antipsychotics as well as selective serotonin reuptake inhibitor was high. Conclusion : KMAP-DD 2017 provides a useful guide for treating the subtypes of major depression, based on expert consensus

Objectives : Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) was produced based on revision of the third version, Korean Medication Algorithm Project for Depressive Disorder 2012 (KMAPDD 2012). KMAP-DD 2017 reflects the latest trends and new research in the treatment of depression. Methods : A total of 144 psychiatrists with excellent clinical experience and academic achievements in treating depression were selected. The survey of KMAP-DD 2017 was sent to them through e-mail. Of these, 79 psychiatrists answered the survey. The survey consisted of 44 questionnaires including seven parts. Each treatment strategy was categorized into three classifications of recommendation as first-line, second-line, and third-line, based on the 95% confidence interval. Results : The results of KMAP-DD 2017 were almost similar to those of KMAP-DD 2012. However, the preference for serotonin-norepinephrine reuptake inhibitor such as venlafaxine was increased, as compared with KMAP-DD 2012. In case of anxious distress and mixed features, the preference for atypical antipsychotics as well as selective serotonin reuptake inhibitor was high. Conclusion : KMAP-DD 2017 provides a useful guide for treating the subtypes of major depression, based on expert consensus